Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. [electronic resource]
Producer: 20191030Description: e409-e418 p. digitalISSN:- 2352-3026
- Aged
- Cyclosporine -- therapeutic use
- Disease-Free Survival
- Drug Therapy, Combination
- Female
- Graft vs Host Disease -- mortality
- HLA Antigens -- metabolism
- Hematopoietic Stem Cell Transplantation -- adverse effects
- Humans
- Immunosuppressive Agents -- therapeutic use
- Male
- Middle Aged
- Mycophenolic Acid -- therapeutic use
- Proportional Hazards Models
- Recurrence
- Sirolimus -- therapeutic use
- Survival Rate
- Transplantation, Homologous
- Treatment Outcome
- Whole-Body Irradiation
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.